Molecular Mechanisms for Lipopolysaccharide-induced Biphasic Activation of Nuclear Factor-κB (NF-κB)*

The nuclear factor-κB (NF-κB) is an important transcription factor necessary for initiating and sustaining inflammatory and immune reactions. The inducers of NF-κB are well characterized, but the molecular mechanisms underlying multiplein vivo NF-κB activation processes are poorly understood. The injection of lipopolysaccharide resulted in a biphasic activation of NF-κB during the 18-h observation period in various organs of mice. The early and late phases of NF-κB activation occurred at 0.5–2 h and 8–12 h, respectively. Platelet-activating factor, which is released in response to lipopolysaccharide injection, was responsible for the activation of the early phase of NF-κB. The early NF-κB activity led to the induction of proinflammatory cytokines, tumor necrosis factor (TNF), and interleukin (IL)-1β, which are known to be efficient inducers of NF-κB. Using the TNF knockout and IL-1 receptor knockout mice, we found that TNF and IL-1β had a role in the second phase activation of NF-κB. These cytokines did promote the synthesis of platelet-activating factor, which in turn induced the secondary activation of NF-κB. These observations describe a novel autoregulatory molecular mechanism for the biphasic activation of NF-κB.

[1]  T. Mak,et al.  Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4 , 2002, Nature.

[2]  T. Lawrence,et al.  Possible new role for NF-κB in the resolution of inflammation , 2001, Nature Medicine.

[3]  S. Im,et al.  Platelet-Activating Factor-Induced Early Activation of NF-κB Plays a Crucial Role for Organ Clearance of Candida albicans1 , 2001, The Journal of Immunology.

[4]  B. Beutler,et al.  The evolution and genetics of innate immunity , 2001, Nature Reviews Genetics.

[5]  D. Goeddel,et al.  Defective Lymphotoxin-β Receptor-Induced NF-κB Transcriptional Activity in NIK-Deficient Mice , 2001, Science.

[6]  B. Aggarwal,et al.  Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-κB , 2000, Annals of the rheumatic diseases.

[7]  K. Jang,et al.  Selective Involvement of Reactive Oxygen Intermediates in Platelet-activating Factor-mediated Activation of NF-κB , 2000, Inflammation.

[8]  L. O’Neill The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. , 2000, Biochemical Society transactions.

[9]  J. Simpson,et al.  A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor Receptor Antagonist) in Patients with Severe Sepsis , 2000, Antimicrobial Agents and Chemotherapy.

[10]  J. Vincent,et al.  Phase II multicenter clinical study of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of sepsis , 2000, Critical care medicine.

[11]  S. Akira,et al.  Unresponsiveness of MyD88-deficient mice to endotoxin. , 1999, Immunity.

[12]  T. Serikawa,et al.  Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-κb-inducing kinase , 1999, Nature Genetics.

[13]  S. Morony,et al.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.

[14]  I. Choi,et al.  Glucocorticoids prevent NF‐κB activation by inhibiting the early release of platelet‐activating factor in response to lipopolysaccharide , 1999, European journal of immunology.

[15]  M. Peppelenbosch,et al.  PHOSPHOLIPASE A2INHIBITORS AND LEUKOTRIENE SYNTHESIS INHIBITORS BLOCK TNF-INDUCED NF-κB ACTIVATION , 1999 .

[16]  B. Johansen,et al.  Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-kappa B and expression of ICAM-1. , 1998, Journal of immunology.

[17]  Z. Cao,et al.  MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. , 1997, Immunity.

[18]  P. Feng,et al.  IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. , 1997, Science.

[19]  S. Im,et al.  Involvement of nuclear factor‐xB in platelet‐activating factor‐mediated tumor necrosis factor‐α expression , 1997 .

[20]  W. Goebel,et al.  Listeria monocytogenes infection of P388D1 macrophages results in a biphasic NF-κB (RelA/p50) activation induced by lipoteichoic acid and bacterial phospholipases and mediated by IκBα and IκBβ degradation , 1997 .

[21]  N. B. Lerner,et al.  Rickettsia rickettsii infection of cultured human endothelial cells induces NF-kappaB activation , 1997, Infection and immunity.

[22]  P. Insel,et al.  Dual role of protein kinase C in the regulation of cPLA2-mediated arachidonic acid release by P2U receptors in MDCK-D1 cells: involvement of MAP kinase-dependent and -independent pathways. , 1997, The Journal of clinical investigation.

[23]  D. Wallach,et al.  MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1 , 1997, Nature.

[24]  Michael Karin,et al.  Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death , 1996, Cell.

[25]  Zhaodan Cao,et al.  TRAF6 is a signal transducer for interleukin-1 , 1996, Nature.

[26]  S. Im,et al.  Augmentation of tumor metastasis by platelet-activating factor. , 1996, Cancer research.

[27]  Z. Cao,et al.  IRAK: A Kinase Associated with the Interleukin-1 Receptor , 1996, Science.

[28]  S. Huong,et al.  Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters , 1995, Journal of virology.

[29]  Jiahuai Han,et al.  Platelet-activating Factor Induces NF-κB Activation through a G Protein-coupled Pathway (*) , 1995, The Journal of Biological Chemistry.

[30]  F. Santini,et al.  Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different pathways for release of arachidonic acid and secretory granules. , 1995, Journal of immunology.

[31]  S. Nourshargh,et al.  Interleukin-1-induced leukocyte extravasation across rat mesenteric microvessels is mediated by platelet-activating factor. , 1995, Blood.

[32]  H. Erdjument-Bromage,et al.  IκB-β regulates the persistent response in a biphasic activation of NF-κB , 1995, Cell.

[33]  G. Camussi,et al.  Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis , 1994, The Journal of experimental medicine.

[34]  W. Shearer,et al.  Activation of NF-KB and Immunoglobulin Expression in Response to Platelet-Activating Factor in a Human B Cell Line , 1994 .

[35]  J. Sedor,et al.  Cell-specific regulation of type II phospholipase A2 expression in rat mesangial cells. , 1993, The Journal of clinical investigation.

[36]  R. Heller,et al.  Cytoplasmic phospholipase A2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the induced synthesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Krönke,et al.  TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced “Acidic” sphingomyelin breakdown , 1992, Cell.

[38]  D. Gingras,et al.  Platelet-activating factor (PAF-acether) enhances the concomitant production of tumour necrosis factor-alpha and interleukin-1 by subsets of human monocytes. , 1991, Immunology.

[39]  G. Camussi,et al.  Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. , 1988, The Journal of biological chemistry.

[40]  D. Baltimore,et al.  Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor , 1988, Cell.

[41]  L. Touqui,et al.  Perspectives in platelet-activating factor research. , 1987, Pharmacological reviews.

[42]  David Baltimore,et al.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences , 1986, Cell.

[43]  J. Mato,et al.  Modulation of lyso-platelet-activating factor: acetyl-CoA acetyltransferase from rat splenic microsomes. The role of calcium ions. , 1985, Biochimica et biophysica acta.

[44]  L. Touqui,et al.  1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle. , 1985, Biochimica et biophysica acta.

[45]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[46]  G. Atsumi,et al.  Regulatory functions of phospholipase A2. , 1997, Critical reviews in immunology.

[47]  E. Kopp,et al.  NF-kappa B and rel proteins in innate immunity. , 1995, Advances in immunology.

[48]  W. J. Johnson,et al.  Interleukin-1 and tumor necrosis factor are not synergistic for human synovial fibroblast PLA2 activation and PGE2 production. , 1988, Prostaglandins.